To assess whether the FLT3-ITD and/or NPM1 mutation status could act as an independent risk factor affecting telomere length in AML patients, a multiple linear regression model considering the presence of the FLT3-ITD and NPM1 mutation and both SNPs was employed. The gene discussed is NPM1; the disease is acute myeloid leukemia.